ADAM17 and cholestasis: Our study identifies increased ADAM17 expression and activity as a proinflammatory driver of liver injury and sickness behavior development in a murine model of cholestasis, and also shows that ADAM17 expression is similarly enhanced in the liver of PBC and PSC patients in close proximity to areas of portal inflammatory cell infiltration, inflammation and hepatocyte injury.